ArticleClinical cancer research : an official journal of the American Association for Cancer Research2011
Primary central nervous system lymphomas: a validation study of array-based comparative genomic hybridization in formalin-fixed paraffin-embedded tumor specimens.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04066920 (Clinical Efficacy and Safety of IBER Salvage Treatment Followed by Ibrutinib Maintenance for Transplant-ineligible Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma), which is not on this map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical Efficacy and Safety of IBER Salvage Treatment Followed by Ibrutinib Maintenance for Transplant-ineligible Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL): a Multicenter, Single-arm, Prospective Phase II Study
Who cites it
38 citing papers in PubMed.
- A Phase II Study Assessing Long-term Response to Ibrutinib Monotherapy in Recurrent or Refractory CNS Lymphoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Trial
- MYC protein expression in primary diffuse large B-cell lymphoma of the central nervous system.PloS one · 2014Trial
- Phase Ib study with expansion of ibrutinib, lenalidomide, and rituximab in patients with relapsed/refractory central nervous system lymphoma.Neuro-oncology · 2025Article
- Review
- Analysis of the genomic landscape of primary central nervous system lymphoma using whole-genome sequencing in Chinese patients.Frontiers of medicine · 2023Article
- Primary central nervous system lymphoma.Nature reviews. Disease primers · 2023Review
- Orelabrutinib Combined With Lenalidomide and Immunochemotherapy for Relapsed/Refractory Primary Central Nervous System Lymphoma: A Retrospective Analysis of Case Series.Frontiers in oncology · 2022Article
- Whole-Genome/Exome Sequencing Uncovers Mutations and Copy Number Variations in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System.Frontiers in genetics · 2022Article
- Review
- Recent advances in the management of primary central nervous system lymphoma.Blood research · 2020Review
- Primary Central Nervous System Lymphoma: Molecular Pathogenesis and Advances in Treatment.Translational oncology · 2019Review
- Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma.Blood · 2019Article
- Analysis of Genomic Alteration in Primary Central Nervous System Lymphoma and the Expression of Some Related Genes.Neoplasia (New York, N.Y.) · 2018Article
- Identification of novel recurrent ETV6-IgH fusions in primary central nervous system lymphoma.Neuro-oncology · 2018Article
- Article
- Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.Cancer discovery · 2017Article
- Diffuse large B-cell lymphoma: can genomics improve treatment options for a curable cancer?Cold Spring Harbor molecular case studies · 2017Review
- The Challenge of Primary Central Nervous System Lymphoma.Hematology/oncology clinics of North America · 2016Review
- Gene Mutation Profiles in Primary Diffuse Large B Cell Lymphoma of Central Nervous System: Next Generation Sequencing Analyses.International journal of molecular sciences · 2016Article
- A specific mutation in TBL1XR1 causes Pierpont syndrome.Journal of medical genetics · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
purposeOnly a limited number of genetic studies have been conducted in primary central nervous system lymphomas (PCNSL), partly due to the rarity of the tumors and the very limited amount of available tissue. In this report, we present the first molecular characterization of copy number abnormalities (CNA) of newly diagnosed PCNSL by array-based comparative genomic hybridization (aCGH) in formalin-fixed paraffin-embedded (FFPE) specimens and compare the results with matched, frozen tumor specimens. EXPERIMENTAL
designWe conducted aCGH in FFPE tissues from PCNSL. Results were compared with matched, paired, frozen tumors.
resultsOur analysis confirmed the good to fair quality and reliability of the data generated from limited amounts of tumoral FFPE tissue. Overall, all PCNSL cases were characterized by highly complex karyotypes, with a median of 23 CNAs per patient (range, 17-47). Overall, 20 chromosomal regions were recurrently found in more than 40% of cases. Deletions of 6p21, 6q, and 9p21.3 and gain of 12q12-q24.33 were the commonest CNAs. Other minimal affected regions were defined, and novel recurrent CNAs affecting single genes were identified in 3q26.32 (TBL1XR1) and 8q12.1 (TOX).
conclusionsThe results obtained are encouraging. Larger archival tissue collections can now be analyzed to complement the still fragmented knowledge we have of the genetic basis of the PCNSL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.